Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 8/20 | 0.48 |
| ▸ | NOS1 | P29475 | 7/20 | 0.48 |
| ▸ | NOS3 | P29474 | 4/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17573027 | 0.93 | NOS2 (0.53) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL23894781 | 0.90 | PRMT5 (0.42) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL15829855 | 0.84 | NOS2 (0.67) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL19171566 | 0.83 | NOS2 (0.51) | KDM5ANOS2NOS1NOS3 | |
| SCHEMBL19356328 | 0.83 | NOS2 (0.60) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL15834091 | 0.82 | NOS2 (0.56) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL19606453 | 0.82 | HRH4 (0.48) | KDM5ANOS2NOS1NOS3MAP3K12 | |
| SCHEMBL15833934 | 0.82 | MAPK10 (0.42) | KDM5ANOS2NOS1NOS3MAP3K12 | |
| SCHEMBL19170614 | 0.81 | NOS2 (0.52) | KDM5ANOS2NOS1NOS3PRMT5 | |
| SCHEMBL18466543 | 0.81 | SYK (0.49) | KDM5ANOS2NOS1NOS3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | KDM5A 11/4885NOS2 454/4885NOS1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.